In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.
about
Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure InfectionsThiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyraseEfficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae InfectionEarly investigational antibiotics for the treatment of acute exacerbations of chronic bronchitis.Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.Targeting bacterial topoisomerases: how to counter mechanisms of resistance.Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Topoisomerases: Resistance versus Sensitivity, How Far We Can Go?In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae.In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents Against Human Mycoplasmas and Ureaplasmas.Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines.Application of Nanoparticle Technologies in the Combat against Anti-Microbial Resistance.Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia.Cellular pharmacokinetics and intracellular activity of gepotidacin against Staphylococcus aureus with different resistance phenotypes in models of cultured phagocytic cells.Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation.Directed evolution of multiple genomic loci allows the prediction of antibiotic resistance.Future Prospects for Neisseria gonorrhoeae Treatment.
P2860
Q33726674-15669C5B-9372-453F-B016-BA997C4C7D66Q33782498-B06B0DAF-5ACA-400D-B096-B5B75CFB03C8Q37203757-1674110A-23C2-4D17-A838-6836F7A4C407Q38769929-84DF7425-143C-4F83-940B-8357B7248512Q38797016-AAD273BB-CF7C-4EAB-96A5-8FAB04812ED6Q38855273-0258BC60-9051-4CF0-B748-471469BDC335Q38949284-0C128317-4C83-4015-82AC-3619887C0D0EQ38958278-47492DF9-8ABC-4114-A52F-EAF0B891B4DFQ38968355-C98D43D6-F4C1-446E-AA7A-A92E72444EABQ39030692-9D94381F-CBA8-4732-8A56-A39290B6594FQ40103287-DA140C44-AB41-43EA-A50A-A951955E3BAAQ40118853-7EBA5FB8-2757-4637-BA13-3AAADC9FCA3BQ47727124-7B09C462-461D-44D7-8B9E-BA0632A42B4FQ47761002-96758D4B-09F7-4FCD-B9F2-71A6576CF4A8Q49874631-04157810-FAFD-4482-B6F3-FF4B02ABE636Q52607037-E8A8661A-5E6A-4091-BE7C-F7B42D4FD2C3Q55348060-1B6F87D9-9F2A-4046-B5FE-61E5202DAF33Q55406005-20A7AB1E-3DA9-47C9-8D0E-16A9327113DA
P2860
In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
In Vitro Activity of Gepotidac ...... ectrum of Bacterial Pathogens.
@en
type
label
In Vitro Activity of Gepotidac ...... ectrum of Bacterial Pathogens.
@en
prefLabel
In Vitro Activity of Gepotidac ...... ectrum of Bacterial Pathogens.
@en
P2093
P2860
P356
P1476
In Vitro Activity of Gepotidac ...... ectrum of Bacterial Pathogens.
@en
P2093
C Jakielaszek
D J Biedenbach
L A Miller
N E Scangarella-Oman
S K Bouchillon
P2860
P304
P356
10.1128/AAC.02820-15
P407
P577
2016-01-04T00:00:00Z